Stockscreener 앱 받기
0.9692
9.32%
0.082
전일 마감가:
$0.8872
열려 있는:
$0.9
하루 거래량:
8.80M
Relative Volume:
2.14
시가총액:
$282.95M
수익:
-
순이익/손실:
$-63.08M
주가수익비율:
-3.5896
EPS:
-0.27
순현금흐름:
$-72.53M
1주 성능:
+16.27%
1개월 성능:
+27.62%
6개월 성능:
+11.70%
1년 성능:
-46.41%
1일 변동 폭
$0.90
$1.01
1주일 범위
$0.80
$1.01
52주 변동 폭
$0.515
$1.979
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
OCGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.9689 | 257.98M | 0 | -63.08M | -72.53M | -0.27 |
|
ONC
Beone Medicines Ltd Adr
|
258.18 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.12 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.29 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.92 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
487.39 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
Ocugen signs term sheet for korean licensing of OCU400 gene therapy - Ophthalmology Times
Ocugen stock rises on Korean licensing deal for gene therapy - Investing.com India
Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea - GuruFocus
Ocugen stock gains on licensing deal (OCGN:NASDAQ) - Seeking Alpha
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of Ocu400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - marketscreener.com
Ocugen inks $11 million gene therapy deal for Korean market - Investing.com Australia
Ocugen inks $11 million gene therapy deal for Korean market By Investing.com - Investing.com Canada
Ocugen announcing signing of term sheet, enter licensing agreement for OCU400 - TipRanks
Ocugen, Inc. Announces Signing Of Binding Term Sheet For The License Of Ocu400 Modifier Gene Therapy For Retinitis Pigmentosa In Korea - marketscreener.com
Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea | OCGN Stock News - GuruFocus
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | OCGN Stock News - GuruFocus
Ocugen, Inc. Announces Signing of Binding Term Sheet for - GlobeNewswire
Ocugen's Blindness Gene Therapy Lands Major Korean Deal: $11M Upfront, 25% Royalties - Stock Titan
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene ... - Bluefield Daily Telegraph
OCGNOcugen Provides Business Update with First Quarter 2025 Financial Results - mx.advfn.com
Malvern-Based Ocugen to Pursue Rare Pediatric Disease Therapy - VISTA.Today
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN
Ocugen Receives Rare Pediatric Disease Designation for OCU410ST - MSN
FDA awards Ocugen drug with Rare Pediatric Disease Designation - Pennsylvania Business Report -
Ocugen’s Gene Therapy OCU410ST Nets Rare Pediatric Disease Designation for ABCA4-Associated Retinopathies - CGTLive®
Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment - MSN
FDA grants Ocugen rare pediatric disease designation as voucher program remains in limbo - The Business Journals
Ocugen Gets FDA Rare Pediatric Disease Label for OCU410ST - marketscreener.com
Ocugen (OCGN) Gains Rare Pediatric Disease Status for Eye Therap - GuruFocus
FDA grants Ocugen’s OCU410ST rare pediatric disease status By Investing.com - Investing.com South Africa
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease - Ocugen
Ocugen Announces Rare Pediatric Disease Designation Granted for - GuruFocus
FDA grants Ocugen’s OCU410ST rare pediatric disease status - Investing.com Australia
FDA Grants Rare Pediatric Disease Designation to OCU410ST from Ocugen (OCGN) | OCGN Stock News - GuruFocus
Ocugen receives Rare Pediatric Disease Designation for OCU410ST - TipRanks
Ocugen Announces Rare Pediatric Disease Designation Granted - GlobeNewswire
FDA Backs Ocugen's Revolutionary Gene Therapy for Rare Childhood BlindnessNo Current Treatment Exists - Stock Titan
Northern Trust Corp Acquires 227,150 Shares of Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish - MSN
Ocugen, Inc. (NASDAQ:OCGN) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy - MSN
Tower Research Capital LLC TRC Has $32,000 Position in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen Provides Business Update with First Quarter 2025 Financial Results - ADVFN
Noble Financial Predicts Ocugen’s Q2 Earnings (NASDAQ:OCGN) - Defense World
Ocugen to Host Q1 2025 Earnings Call and Business Update on May 9 - MSN
Ocugen stock price target cut to $7 by H.C. Wainwright - Investing.com Canada
Ocugen (NASDAQ:OCGN) Receives Buy Rating from Chardan Capital - Defense World
Ocugen (OCGN) Receives Ongoing "Buy" Rating from Chardan Capital - GuruFocus
Ocugen (OCGN) Maintains 'Buy' Rating Despite Price Target Adjust - GuruFocus
Ocugen (OCGN) Price Target Reduced by H.C. Wainwright | OCGN Sto - GuruFocus
The Analyst Verdict: Ocugen In The Eyes Of 5 Experts - Benzinga
Ocugen outlines 2025 milestones for gene therapy programs with BLA filings on track - MSN
Barclays PLC Decreases Holdings in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen, Inc. (NASDAQ:OCGN) Q1 2025 Earnings Call Transcript - Insider Monkey
Ocugen: Q1 Earnings Snapshot - New Haven Register
Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ... - Yahoo
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
오큐젠 주식 (OCGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Castillo Kirsten | Director |
Nov 22 '24 |
Buy |
0.91 |
25,000 |
22,848 |
75,000 |
0.00%
0.24%
자본화:
|
볼륨(24시간):